All News
Consequences of TNF inhibition (3.18.2022)
This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleRheumNow Live is Coming to Town (3.11.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticlePsoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib
Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.
Read ArticleBaricitinib’s COVID-19 Efficacy in the RECOVERY Trial
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Hand OA and Heroes in Rheumatology (2.11.2022)
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
Read ArticleThe Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...
Read ArticleRisk vs. Benefit Lessons from the ORAL Surveillance Study
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
Read ArticleMMWR: Booster Vaccine Efficacy in Immunosuppressed Patients
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
Read ArticleFDA Approves Skyrizi for Active Psoriatic Arthritis
On Friday, the U.S. Food and Drug Administration (FDA) approved risankizumab-rzaa (Skyrizi) for the treatment of adults with active psoriatic arthritis (PsA), with similar dosing in plaque psoriasis - a single 150mg subcutaneous injection four times a year after two starter doses (at weeks 0
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
The Overpricing of Drugs (1.14.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
Read Article2021 Rheumatology Year in Review
Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read ArticleLinks:
Best of 2021: Jack of All Subspecialties
It's great to be a rheumatologist, but boy, it's getting harder and harder. You have to be a jack of all trades. You have to be good at cardiovascular disease, osteoporosis, vaccination, inflammatory bowel disease - it just never ends. This and more, as Dr. Cush summarizes more than a dozen journal articles, news reports and questions + cases.
Read Article